产品
编 号：F196901
分子式：C26H23N5O2
分子量：437.49
分子式：C26H23N5O2
分子量：437.49
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
结构图
CAS No: 1637771-14-2
产品详情
生物活性：
Alobresib (GS-5829) is a BET bromodomain inhibitor, which represents a highly effective therapeutics agent against recurrent/chemotherapy resistant uterine serous carcinoma (USC) overexpressing c-Myc. Alobresib can be used in the metastatic castration-resistant prostate cancer (mCRPC) research.
体内研究：
Alobresib (10 和 20 mg/kg；口服；每天两次；持续 28 天) 在雌性 CB17/lcrHsd-Prkd/scid 小鼠中抑制 USC-ARK2 异种移植肿瘤的生长。与 每天接受 JQ1 (50 mg/kg/天 ip) 处理及媒介物对照小鼠相比，Alobresib 在小鼠体内表现出明显更慢的肿瘤生长速率。 Alobresib (10 和 20 mg/kg；口服；每天两次；持续 28 天) 具有良好的耐受性，与对照组相比，对体重没有明显影响。Animal Model:Female CB17/lcrHsd-Prkd/scid mice (15-19 g) bearing USC-ARK2 tumors
Dosage:10 and 20 mg/kg
Administration:Oral; twice-daily; 28 days
Result:Exhibited a significantly slower rate of tumor growth, compared with vehicle control and to mice undergoing daily treatment with JQ1 (50 mg/kg/day i.p.).
体外研究：
Alobresib (0.1 nM-100 μM；72 小时) 抑制原发性子宫浆液性癌 (USC) 细胞系中的细胞增殖。
Alobresib (GS-5829) is a BET bromodomain inhibitor, which represents a highly effective therapeutics agent against recurrent/chemotherapy resistant uterine serous carcinoma (USC) overexpressing c-Myc. Alobresib can be used in the metastatic castration-resistant prostate cancer (mCRPC) research.
体内研究：
Alobresib (10 和 20 mg/kg；口服；每天两次；持续 28 天) 在雌性 CB17/lcrHsd-Prkd/scid 小鼠中抑制 USC-ARK2 异种移植肿瘤的生长。与 每天接受 JQ1 (50 mg/kg/天 ip) 处理及媒介物对照小鼠相比，Alobresib 在小鼠体内表现出明显更慢的肿瘤生长速率。 Alobresib (10 和 20 mg/kg；口服；每天两次；持续 28 天) 具有良好的耐受性，与对照组相比，对体重没有明显影响。Animal Model:Female CB17/lcrHsd-Prkd/scid mice (15-19 g) bearing USC-ARK2 tumors
Dosage:10 and 20 mg/kg
Administration:Oral; twice-daily; 28 days
Result:Exhibited a significantly slower rate of tumor growth, compared with vehicle control and to mice undergoing daily treatment with JQ1 (50 mg/kg/day i.p.).
体外研究：
Alobresib (0.1 nM-100 μM；72 小时) 抑制原发性子宫浆液性癌 (USC) 细胞系中的细胞增殖。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备